RUGBY, England, Jan. 20 /PRNewswire/ -- Mediwatch, the innovative UK manufacturer of high tech screening and diagnostic systems for urological disorders, announced today that it has received marketing approval from the US Food and Drug Administration (FDA) for the Portascan(R) portable bladder scanner in the USA.
The state-of-the-art portable diagnostic will be used to screen patients suffering from prostate and bladder disorders, incontinence and those requiring catheterization. Doctors' offices, outpatient clinics, hospital emergency departments and nursing homes are all potential users of the Portascan, where its level of accuracy gives it a major advantage over its competitors This approval provides Mediwatch with access to the lucrative US bladder screening market, currently valued at between $15 and $20 million per annum.
Commenting on this development, Philip Stimpson, CEO, said, "Breaking into the US market represents a significant milestone for Mediwatch. We are in advanced stages to conclude a distribution agreement with a large, well- established international company that is already selling into closely related markets. Although this is our first venture into the US, we have already signed similar agreements with multi-nationals to distribute our products across Europe."
Issued on behalf of Mediwatch by De Facto Communications plc
CONTACT: Yvonne Alexander of De Facto, +1-44-20-7496-3316, email@example.com; or Philip Stimpson of Mediwatch, +44-788-547-888, firstname.lastname@example.org